Galectin-1 and semaphorin-3A are two soluble factors conferring t-cell immunosuppression to bone marrow mesenchymal stem cell

Stem Cells and Development

Volumn 19, Issue 7, 2010, Pages 1075-1079

  Lepelletier, Yves ^a   Lecourt, Séverine ^b   Renand, Amédée ^a   Arnulf, Bertrand ^c   Vanneaux, Valérie ^b   Fermand, Jean Paul ^c   Menasché, Philippe ^d   Domet, Thomas ^b   Marolleau, Jean Pierre ^e   Hermine, Olivier ^a,b   Larghero, Jérôme ^b,c,f  

^a CNRS   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; ENDOGLIN; GALECTIN 1; HERMES ANTIGEN; INTERLEUKIN 10; MICROSOMAL AMINOPEPTIDASE; NEUROPILIN 1; SEMAPHORIN 3A; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER;

ARTICLE; BONE MARROW; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; BONE MARROW CELL; CYTOLOGY; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM;

ANIMALIA;

ANIMALS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL PROLIFERATION; GALECTIN 1; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STROMAL CELLS; SEMAPHORIN-3A; T-LYMPHOCYTES;

EID: 77954932147     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2009.0212     Document Type: Article

References (27)

1. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
2. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, Dj Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
3. Majumdar MK, M Keane-Moore, D Buyaner, WB Hardy, MA Moorman, KR McIntosh and JD Mosca. (2003). Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10:228-241.
4. Bartholomew A, C Sturgeon, M Siatskas, K Ferrer, K McIntosh, S Patil, W Hardy, S Devine, D Ucker, R Deans, A Moseley and R Hoffman. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42-48.
5. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
6. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, F Vinante, P Romagnani, E Maggi, S Romagnani and F Annunziato. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
7. Spaggiari GM, A Capobianco, S Becchetti, MC Mingari and L Moretta. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484-1490.
8. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
9. Augello A, R Tasso, SM Negrini, A Amateis, F Indiveri, R Cancedda and G Pennesi. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35:1482-1490.
10. Rasmusson I, O Ringden, B Sundberg and K Le Blanc. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76:1208-1213.
11. Nauta AJ and WE Fibbe. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506.
12. Kadri T, JJ Lataillade, C Doucet, A Marie, I Ernou, P Bourin, R Joubert-Caron, M Caron and D Lutomski. (2005). Proteomic study of Galectin-1 expression in human mesenchymal stem cells. Stem Cells Dev 14:204-212.
13. Hsieh SH, NW Ying, MH Wu, WF Chiang, CL Hsu, TY Wong, YT Jin, TM Hong and YL Chen. (2008). Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27:3746-3753.
14. Tordjman R, Y Lepelletier, V Lemarchandel, M Cambot, P Gaulard, O Hermine and PH Romeo. (2002). A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 3:477-482.
15. Lepelletier Y, IC Moura, R Hadj-Slimane, A Renand, S Fiorentino, C Baude, A Shirvan, A Barzilai and O Hermine. (2006). Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 36:1782-1793.
16. Catalano A, P Caprari, S Moretti, M Faronato, L Tamagnone and A Procopio. (2006). Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 107:3321-3329.
17. Kikutani H and A Kumanogoh. (2003). Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol 3:159-167.
18. Arnulf B, S Lecourt, J Soulier, B Ternaux, MN Lacassagne, A Crinquette, J Dessoly, AK Sciaini, M Benbunan, C Chomienne, JP Fermand, JP Marolleau and J Larghero. (2007). Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21:158-163.
19. Larghero J, D Farge, A Braccini, S Lecourt, A Scherberich, E Fois, F Verrecchia, T Daikeler, E Gluckman, A Tyndall and C Bocelli-Tyndall. (2008). Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 67:443-449.
20. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
21. Puissant B, C Barreau, P Bourin, C Clavel, J Corre, C Bousquet, C Taureau, B Cousin, M Abbal, P Laharrague, L Penicaud, L Casteilla and A Blancher. (2005). Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 129:118-129.
22. Djouad F, V Fritz, F Apparailly, P Louis-Plence, C Bony, J Sany, C Jorgensen and D Noel. (2005). Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 52:1595-1603.
23. Le Blanc K, I Rasmusson, C Gotherstrom, C Seidel, B Sundberg, M Sundin, K Rosendahl, C Tammik and O Ringden. (2004). Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin- activated lymphocytes. Scand J Immunol 60:307-315.
24. Luo Y, D Raible and JA Raper. (1993). Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75:217-227.
25. Lepelletier Y, S Smaniotto, R Hadj-Slimane, DM Villa-Verde, AC Nogueira, M Dardenne, O Hermine and W Savino. (2007). Control of human thymocyte migration by Neuropilin-1/Semaphorin-3A-mediated interactions. Proc Natl Acad Sci USA 104:5545-5550.
26. Garin MI, CC Chu, D Golshayan, E Cernuda-Morollon, R Wait and RI Lechler. (2007). Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109:2058-2065.
27. Pedemonte E, F Benvenuto, S Casazza, G Mancardi, JR Oksenberg, A Uccelli and SE Baranzini. (2007). The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics 8:65.